Economic burden in Chinese patients with diabetes mellitus using electronic insurance claims data

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Huang, Yunyu ^a,b   Vemer, Pepijn ^a,c   Zhu, Jingjing ^b   Postma, Maarten J ^a,c   Chen, Wen ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; GLUCOSE BLOOD LEVEL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHINESE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC FOOT; ECONOMIC ASPECT; ELECTRONIC HEALTH RECORD; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; INFORMATION SYSTEM; KIDNEY DISEASE; KRUSKAL WALLIS TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NEUROPATHY; REIMBURSEMENT; RETINOPATHY; RETROSPECTIVE STUDY; URBAN POPULATION; ADOLESCENT; CHI SQUARE DISTRIBUTION; CHILD; CHINA; COST OF ILLNESS; CROSS-SECTIONAL STUDY; DIABETIC COMPLICATION; ECONOMICS; HEALTH CARE DELIVERY; INFANT; METABOLISM; MIDDLE AGED; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BLOOD GLUCOSE; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CHINA; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; DELIVERY OF HEALTH CARE; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT; INFANT, NEWBORN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84991434372     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159297     Document Type: Article

References (34)

1. Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes research and clinical practice. 2010; 87(3):293-301. Epub 2010/02/23. doi: 10.1016/j.diabres.2010.01.026 PMID: 20171754.
2. American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes care. 2013; 36(4):1033-46. Epub 2013/03/08. doi: 10.2337/dc12-2625 PMID: 23468086; PubMed Central PMCID: PMCPmc3609540.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care. 2004; 27(5):1047-53. Epub 2004/04/28. PMID: 15111519.
4. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. The New England journal of medicine. 2010; 362(12):1090-101. Epub 2010/03/26. doi: 10.1056/NEJMoa0908292 PMID: 20335585.
5. International Diabetes Federation. Diabetes Atlas 6th edition. 2014 Update 2014 [cited 2014]. Available from: http://www.idf.org/sites/default/files/Atlas-poster-2014-EN.pdf.
6. Shu T, Liu H, Goss FR, Yang W, Zhou L, Bates DW, et al. EHR adoption across China's tertiary hospitals: a cross-sectional observational study. International journal of medical informatics. 2014; 83 (2):113-21. Epub 2013/11/23. doi: 10.1016/j.ijmedinf.2013.08.008 PMID: 24262068.
7. Chinese Diabetes Society. Chinese guideline of prevention and treatment for Type 2 Diabetes Mellitus. Chin J Diabetes Mellitus. 2014; 6(7):447-98.
8. Ji L, Wu J, Chen Y, Rong H, Hou J, Feng B, et al. Analysis of use of hypoglycemic medication of patients with type 2 diabetes mellitus in Chinese middle and big cities. Chin Pharm J. 2012; 47(9):736-38.
9. Zhang D, Tang Z, Li L, Gu L, Xue D. A systematic review on prevalence rate of diabetes in 2001-2010 in China. Shanghai Journal of Preventive Medicine. 2012; 24(9):492-95.
10. Zheng Y, Ji L, Wu J. Cost of-illness studies of diabetes mellitus in China: A systematic review. Chin J Endocrinol Metab. 2012; 28(10):821-25.
11. Xie X, Vondeling H. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2008; 11 Suppl 1:S23-32. Epub 2008/04/17. doi: 10.1111/j.1524-4733.2008.00363.x PMID: 18387063.
12. Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, et al. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. Advances in therapy. 2008; 25(8):752-74. Epub 2008/08/16. doi: 10.1007/s12325-008-0080-4 PMID: 18704282.
13. Palmer JL, Beaudet A, White J, Plun-Favreau J, Smith-Palmer J. Cost-effectiveness of biphasic insulin aspart versus insulin glargine in patients with type 2 diabetes in China. Advances in therapy. 2010; 27 (11):814-27. Epub 2010/11/10. doi: 10.1007/s12325-010-0078-6 PMID: 21061114.
14. Yang L, Christensen T, Sun F, Chang J. Cost-effectiveness of switching patients with type 2 diabetes from insulin glargine to insulin detemir in Chinese setting: a health economic model based on the PREDICTIVE study. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2012; 15(1 Suppl):S56-9. Epub 2012/02/01. doi: 10.1016/j.jval.2011.11.018 PMID: 22265068.
15. Gao L, Zhao FL, Li SC. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China. International journal of technology assessment in health care. 2012; 28(4):436-44. Epub 2012/09/26. doi: 10.1017/s0266462312000608 PMID: 23006540.
16. Deng J, Gu S, Shao H, Dong H, Zou D, Shi L. Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. Journal of medical economics. 2015; 18(11):974-89. Epub 2015/07/03. doi: 10.3111/13696998.2015.1067622 PMID: 26134916.
17. Geng J, Yu H, Mao Y, Zhang P, Chen Y. Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. PharmacoEconomics. 2015; 33(6):581-97. Epub 2015/03/05. doi: 10.1007/s40273-015-0266-y PMID: 25736235.
18. Wei F, Xu Y. HZ was elected as the role model city for exellecnt electronic social security system. hangzhoucom.2013.
19. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. The Cochrane database of systematic reviews. 2003;(3: ):Cd003053. Epub 2003/08/15. doi: 10.1002/14651858.cd003053 PMID: 12917943.
20. Li Q, Huang X, Gao R, Lu F. Discussion on developing a data management plan and its key factors in clinical study based on electronic data capture system. J Chin Integr Med. 2012; 10(8):841-46.
21. National Bureau of Statistics of China. China statistical yearbook 20112012.
22. Hu H, Sawhney M, Shi L, Duan S, Yu Y, Wu Z, et al. A systematic review of the direct economic burden of type 2 diabetes in china. Diabetes therapy: research, treatment and education of diabetes and related disorders. 2015; 6(1):7-16. Epub 2015/02/06. doi: 10.1007/s13300-015-0096-0 PMID:25652613; PubMed Central PMCID: PMCPmc4374079.
23. Wang W, McGreevey WP, Fu C, Zhan S, Luan R, Chen W, et al. Type 2 diabetes mellitus in China: a preventable economic burden. The American journal of managed care. 2009; 15(9):593-601. Epub 2009/09/15. PMID: 19747024.
24. Chen X, Tang L, Chen H, Zhao L, Hu S. Assessing the impact of complications on the costs of Type 2 diabetes in urban China. Chin J Diabetes. 2003; 11(4):238-41.
25. Qiu Y, Ye L, Li X, Lu W. Eeonomie burden of type 2 diabetes mellitus in Shanghai. Chinese Health Resources. 2005; 8(2):69-71.
26. Zhang Z, Chen J, Tang Z, Hu R, Lu B. Study on direct health expenditure of diabetes mellitus in China. Chinese Health Resources. 2007; 10(3):162-68.
27. Wang W, Fu CW, Pan CY, Chen W, Zhan S, Luan R, et al. How do type 2 diabetes mellitus-related chronic complications impact direct medical cost in four major cities of urban China? Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2009; 12 (6):923-9. Epub 2009/10/14. doi: 10.1111/j.1524-4733.2009.00561.x PMID: 19824187.
28. Yang W, Zhao W, Xiao J, Li R, Zhang P, Kissimova-Skarbek K, et al. Medical care and payment for diabetes in China: enormous threat and great opportunity. PloS one. 2012; 7(9):e39513. Epub 2012/10/11. doi: 10.1371/journal.pone.0039513 PMID: 23049727; PubMed Central PMCID: PMCPmc3458850.
29. Liu K, Wang M. Economic burden of main chronic non-infectious diseases in China. Chinese Health Economics. 2005; 24(10):77-80.
30. HZ Bureau of Statistics. HZ Statistical Yearbook 2012 2012 [cited 2012 20 Nov]. Available from: http://www.hzstats.gov.cn/web/ShowNews.aspx?id=iyuczsWwYFQ=.
31. Hu S, Liu G, Xu Z, Li D, Hu Y. Current Status of Epidemic and Economic Burden of Diabetes Mellitus in China. Chinese Health Economics. 2008; 27(8):5-8.
32. He M, Li B, Bian Y. The structure analysis of hospitalization costs on the diabetics of in-patient. Chinese Health Economics. 2009; 28(11):22-4.
33. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. 2012.
34. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group. Diabetes care. 2000; 23 (10):1516-26. Epub 2000/10/07. PMID: 11023146.